MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Max Healthcare Institute has submitted its Annual Secretarial Compliance Report for FY2024-25, filed under SEBI Regulation 24A by practicing company secretary DPV & Associates LLP. The report confirms NIL observations, deviations, or fines during the review period, indicating full compliance with SEBI Listing Regulations, Insider Trading rules, and Secretarial Standards. All mandatory parameters — board policies, website disclosures, related party transactions, subsidiary disclosures, and insider trading compliance — are confirmed as compliant, with no action taken by SEBI or stock exchanges against the company. A prior observation regarding a 40-day delay in appointing a Woman Independent Director after Ms. Harmeen Mehta's April 2023 resignation has been disclosed as previously reported and subsequently remediated by appointing Ms. Amrita Gangotra in August 2023.
This is a routine annual regulatory filing with no new adverse findings, which reinforces confidence in Max Healthcare's corporate governance. Investors are unlikely to see any material stock price reaction as the report confirms clean compliance for the current year, with the past woman director appointment delay already addressed.